Milrinone
From Wikipedia, the free encyclopedia
 |
|
|
Milrinone
|
|
| Systematic (IUPAC) name | |
| 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile | |
| Identifiers | |
| CAS number | 78415-72-2 |
| ATC code | C01CE02 |
| PubChem | 4197 |
| DrugBank | APRD00010 |
| Chemical data | |
| Formula | C12H9N3O |
| Mol. weight | 211.219 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 70 to 80% |
| Metabolism | ? |
| Half life | 2.3 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Milrinone is a phosphodiesterase III inhibitor. It potentiates the effect of cyclic adenosine monophosphate (cAMP).
Milrinone also enhances relaxation of the left ventricle by increasing Ca2+-ATPase activity on the cardiac sarcoplasmic reticulum. This increases calcium ion uptake.
It has positive inotropic, vasodilating and minimal chronotropic effects. It is used in the management of heart failure only when conventional treatment with vasodilators and diuretics has proven insufficient. This is due to the potentially fatal adverse effects of milrinone, including ventricular arrhythmias.
Whereas beneficial hemodynamic (US English)/haemodynamic (British English) effects are shown (at least short-term), several studies have shown no or a negative effect on mortality rates of hospitalized patients receiving milrinone.
[edit] See also
[edit] External links
 |
This medical article is a stub. You can help Wikipedia by expanding it. |
| Selective Phosphodiesterase inhibitors (C01CE, G04BE)edit | ||
|---|---|---|
| PDE1: | ||
| PDE2: | ||
| PDE3: |
Amrinone, Bucladesine, Enoximone, Milrinone |
|
| PDE4: | ||
| PDE5: | ||
